Tags

Type your tag names separated by a space and hit enter

Potential therapeutic agents against COVID-19: What we know so far.
J Chin Med Assoc. 2020 06; 83(6):534-536.JC

Abstract

The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.

Authors+Show Affiliations

Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32243270

Citation

Lu, Chih-Chia, et al. "Potential Therapeutic Agents Against COVID-19: what We Know so Far." Journal of the Chinese Medical Association : JCMA, vol. 83, no. 6, 2020, pp. 534-536.
Lu CC, Chen MY, Lee WS, et al. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020;83(6):534-536.
Lu, C. C., Chen, M. Y., Lee, W. S., & Chang, Y. L. (2020). Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association : JCMA, 83(6), 534-536. https://doi.org/10.1097/JCMA.0000000000000318
Lu CC, et al. Potential Therapeutic Agents Against COVID-19: what We Know so Far. J Chin Med Assoc. 2020;83(6):534-536. PubMed PMID: 32243270.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential therapeutic agents against COVID-19: What we know so far. AU - Lu,Chih-Chia, AU - Chen,Mei-Yu, AU - Lee,Wan-Shin, AU - Chang,Yuh-Lih, PY - 2020/4/4/pubmed PY - 2020/6/17/medline PY - 2020/4/4/entrez SP - 534 EP - 536 JF - Journal of the Chinese Medical Association : JCMA JO - J Chin Med Assoc VL - 83 IS - 6 N2 - The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19. SN - 1728-7731 UR - https://www.unboundmedicine.com/medline/citation/32243270/Potential_therapeutic_agents_against_COVID_19:_What_we_know_so_far_ L2 - https://Insights.ovid.com/pubmed?pmid=32243270 DB - PRIME DP - Unbound Medicine ER -